Premium
Efficacy and safety of etanercept for postoperative pyoderma gangrenosum after infliximab serum sickness
Author(s) -
Ariane Molka,
Bouaziz JeanDavid,
de Masson Adèle,
Jachiet Marie,
Bagot Martine,
Lepelletier Clémence
Publication year - 2018
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12774
Subject(s) - pyoderma gangrenosum , medicine , infliximab , etanercept , dermatology , surgery , tumor necrosis factor alpha , disease
Abstract Non‐peristomal postoperative pyoderma gangrenosum (PPG) is a rare subtype of pyoderma gangrenosum that occurs in the early postoperative period at surgical incisions, most commonly after breast surgery. Early diagnosis and treatment is essential to prevent severe scaring. TNF‐alpha inhibitor infliximab was reported to be efficient in treatment of PPG refractory to systemic corticosteroids. However infliximab can be not well tolerated. We report the first case of etanercept efficacy in post‐plastic breast surgery pyoderma gangrenosum after infliximab serum sickness.